Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...